NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage biotechnology company focused on addressing the unmet therapeutic needs of the global anti-infective market. The Company�s Aganocide compounds, led by NVC-422, are patented, synthetic molecules with a spectrum of activity against bacteria, viruses and fungi. The Company focuses on the following therapeutic markets: Dermatology, Ophthalmology and Urology. The Company�s irrigation solution containing NVC-422 is in Phase II clinical studies, with the goal of reducing the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections. The Company is also developing another class of molecule, NeutroPhase, which is an FDA 510(k)-cleared product for advanced wound care.